Pfizer VS Moderna Third Quarter Earnings And Revenue

It's evident that big pharma giant Moderna (NASDAQ: MRNA) is going through troubled times. Worse, it's dragging other big Pharma giants with it.

Why Many parents are concerned about the effect of the coronavirus pandemic on their children.

Below stocks have been added to my watchlist.

Moderna reported its financial results for the fourth quarter on Thursday. Shares are up nearly 15%.

If you are still in profit, dump Moderna stock now and wait for re-entry at a much lower zone.

Compared to its peers like Johnson and Johnson, and Merck, who are also vaccine manufacturers, Pfizer is a better bet and gives higher expected returns.

Speaking on mRNA-1273 and its effectiveness in trials against Omicron, Dr Paul Burton said: “It’s highly effective, and it’s extremely safe.

This week I take a look at two stalwarts in the pharmaceutical industry, and the effect they have had on investors in the race for a COVID-19 vaccine.

AstraZeneca will sell its vaccine to governments at significantly lower prices as compared to Pfizer and Moderna.